Trial Profile
A retrospective study evaluating anti-hyperglycemic effect of Saroglitazar in patients with diabetic dyslipidemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2017
Price :
$35
*
At a glance
- Drugs Saroglitazar (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 18 Jul 2017 New trial record
- 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association